PROBIOTICS IN TREATMENT AND PREVENTION OF NEUROGENIC BLADDER INFECTIOUS COMPLICATIONS
Abstract
Neurogenic bladder is a dysfunction of the bladder caused by congenital or acquired pathology of the nervous system, is a common pathological condition, manifests itself by the inability to carry out voluntary reflex accumulation and excretion of urine due to organic and functional damage to nerve centers and pathways, and significantly complicates the quality of life of patients. Neurogenic bladder is often accompanied by myofascial syndrome, pelvic venous congestion syndrome, and infectious complications.
Objective of the study. To evaluate the effectiveness of probiotics in the prevention of symptomatic bladder infection in patients with bladder neuropathy according to data presented in Russian and foreign literature.
Methods of the study. The search for literary sources from 1993 to 2023 was carried out in the databases CENTRAL, MEDLINE and EMBASE, conference materials, the search portal of the International Clinical Trials Registry Platform (ICTRP) for randomized controlled trials dedicated to the use of probiotics for the prevention of bladder infection in patients with bladder neuropathy.
Results. Three studies involving 109 patients met the necessary RCT criteria. In these studies, the effectiveness of introducing probiotics into the bladder to create a harmless colony of microorganisms in the urinary tract in patients with bladder dysfunction was investigated.
Conclusions. The relative safety of introducing probiotics into the bladder to create a harmless colony of microorganisms in the urinary tract in patients with bladder dysfunction is shown. The effectiveness of using probiotics to prevent the development of infectious complications in patients with neurogenic bladder has not been proven. Further carefully planned research is needed.
About the Authors
S. V. Popov
СПб ГБУЗ «Клиническая больница Святителя Луки»
Russian Federation
Russian Federation
R. G. Huseynov
СПб ГБУЗ «Клиническая больница Святителя Луки»
Russian Federation
Russian Federation
K. V. Sivak
СПб ГБУЗ «Клиническая больница Святителя Луки»
Russian Federation
Russian Federation
V. V. Perepelitsa
СПб ГБУЗ «Клиническая больница Святителя Луки»
Russian Federation
Russian Federation
T. A. Leliavina
СПб ГБУЗ «Клиническая больница Святителя Луки»
Russian Federation
Russian Federation
References
1. Panicker JN. Neurogenic Bladder: Epidemiology, Diagnosis, and Management. Semin Neurol. 2020 Oct;40(5):569-579. doi: 10.1055/s-0040-1713876. Epub 2020 Oct 16. (in Engl)
2. DeWitt-Foy ME, Elliott SP.Neurogenic Bladder: Assessment and Operative Management. Urol Clin North Am. 2022 Aug;49(3):519-532. doi: 10.1016/j.ucl.2022.04.010. Epub 2022 Jun 30. (in Engl)
3. Lee JK.Neurogenic Bladder Management. Radiol Technol. 2021 Jan;92(3):281-295. (in Engl)
4. Al-Shaiji TF, Al-Yousef RJ, El-Nahas AR, Awad AT, Almutairi MF, Al-Terki AE.Time of onset and factors associated with delayed response post intradetrusor injection of onabotulinumtoxin a in patients with neurogenic and idiopathic overactive bladder syndrome. Urol Ann. 2023 Apr-Jun;15(2):133-137. (in Engl)
5. Romo PGB, Smith CP, Cox A, Averbeck MA, Dowling C, Beckford C, Manohar P, Duran S, Cameron AP.Non-surgical urologic management of neurogenic bladder after spinal cord injury. World J Urol. 2018 Oct;36(10):1555-1568. (in Engl)
6. Darouiche RO, Thornby JI, Cerra-Stewart C, Donovan WH, Hull RA. Bacterial interference for prevention of urinary tract infection: a prospective, randomized, placebo‐controlled, double‐blind pilot trial. Clinical Infectious Diseases2005;41(10):1531. (in Engl)
7. Darouiche RO, Green BG, Donovan WH, Chen D, Schwartz M, Merritt J, et al. Multicenter randomized controlled trial of bacterial interference for prevention of urinary tract infection in patients with neurogenic bladder. Urology2011;78(2):341-6. (in Engl)
8. Köves B, Salvador E, Grönberg‐Hernández J, Zdziarski J, Wullt B, Svanborg C, et al. Rare emergence of symptoms during long‐term asymptomatic Escherichia coli 83972 carriage without an altered virulence factor repertoire.Journal of Urology 2014;191(2):519-28. (in Engl)
9. Sunden F, Hakansson L, Ljunggren E, Wullt B. Escherichia coli 83972 bacteriuria protects against recurrent lower urinary tract infections in patients with incomplete bladder emptying. Journal of Urology 2010;184(1):179-85. (in Engl)
10. Sundén F, Håkansson L, Ljunggren E, Wullt B. Bacterial interference is deliberate colonization with Escherichia coli 83972 an alternative treatment for patients with recurrent urinary tract infection?. International Journal of Antimicrobial Agents 2006;28 Suppl 1:S26-9. (in Engl)
11. Czaja CA, Stapleton AE, Yarova Yarovaya Y, Stamm WE. Phase I trial of a Lactobacillus crispatus vaginal suppository for prevention of recurrent urinary tract infection in women. Infectious Diseases in Obstetrics & Gynecology2007:35387. (in Engl)
12. Kontiokari T, Sundqvist K, Nuutinen M, Pokka T, Koskela M, Uhari M. Randomised trial of cranberry‐lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women. BMJ 2001;322(7302):1571. (in Engl)
13. Lee SJ, Kim HJ, Shim YH, Lee JW. The effect of probiotic prophylaxis for preventing recurrent urinary tract infection in children with persistant primary vesicoureteral reflux [abstract no: COD. PP 81]. Pediatric Nephrology2006;21(10):1542. (in Engl)
14. Lee SJ, Shim YH, Cho SJ, Lee JW. Probiotics prophylaxis in children with persistent primary vesicoureteral reflux.Pediatric Nephrology 2007;22(9):1315-20. (in Engl)
15. Mohseni MJ, Aryan Z, Emamzadeh‐Fard S, Paydary K, Mofid V, Joudaki H, et al. Combination of probiotics and antibiotics in the prevention of recurrent urinary tract infection in children. Iranian Journal of Pediatrics2013;23(4):430-8. (in Engl)
16. Beerepoot MA, Heijer CD, Penders J, Prins JM, Stobberingh EE, Geerlings SE. Predictive value of Escherichia coli susceptibility in strains causing asymptomatic bacteriuria for women with recurrent symptomatic urinary tract infections receiving prophylaxis. Clinical Microbiology & Infection 2012;18(4):E84-90. (in Engl)
17. Mark Haran, Madeleine King, Martin Stockler, Obad Marial, Bonne Lee, 2017. «Validity of the SF-36 Health Survey as an outcome measure for trials in people with spinal cord injury,»CHERE, University of Technology, Sydney. Working Papers. 2017;4:1-8. (in Engl)
18. Beerepoot MA, Wal WM, Nys S. Lactobacillus rhamnosus gr-1 and l. Reuteri rc-14 versus trimethoprim‐sulfamethoxazole (TMP/SMX) in the prevention of recurrent urinary tract infections (RUTIs) in postmenopausal women: a randomized double-blind non-inferiority trial [abstract no: L1-1656a]. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 2009 Sep 12-15; San Francisco (CA). 2009: 15-27. (in Engl)
19. Schaeffer EM. Re: Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in postmenopausal women. Journal of Urology 2013;189(4):1332-3. (in Engl)
20. Jones EA. Probiotics improvement of gastrointestinal and genitourinary health in girls with spina bifida (H-23245).clinicaltrials.gov/ct2/show/NCT00767988 (first received 8 October 2008). (in Engl)
21. Roth DR. H-23187: Probiotic prophylaxis against recurrent pediatric urinary tract infection.clinicaltrials.gov/ct2/show/NCT00789464 (first received 10 November 2008):33-49. (in Engl)
22. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. (in Engl)
23. Reid G, Bruce AW, Taylor M. Influence of three-day antimicrobial therapy and lactobacillus vaginal suppositories on recurrence of urinary tract infections. Clinical Therapeutics 1992;14(1):11-16. (in Engl)
24. Lee BB, Toh SL, Ryan S, Simpson JM, Clezy K, Bossa L, et al. Probiotics [LGG-BB12 or RC14-GR1] versus placebo as prophylaxis for urinary tract infection in persons with spinal cord injury [ProSCIUTTU]: a study protocol for a randomised controlled trial. BMC Urology 2016;16:18. (in Engl)
25. Toh SL, Lee BS, Ryan S, Simpson J. Prophylaxis of spinal cord injury urinary tract infection therapeutic trial (ProSCIUTTU): protocol [abstract]. 53rd ISCoS Annual Scientific Meeting; 2014 Sep 2-4; Maastricht, Netherlands. 2014. (in Engl)
26. Barrons R, Tassone D. Use of Lactobacillus probiotics for bacterial genitourinary infections in women: a review.Clinical Therapeutics 2008;30(3):453-68. (in Engl)
27. Paediatrics Manual: The Children's Hospital at Westmead Handbook. 2nd Edition. Sydney: McGraw‐Hill / H. Kilham [et al.] // - 2009. – Handbook, 2nd Edition 2nd Edition Р. 79. (in Engl)
28. Darouiche RO, Donovan WH, Terzo M, Thornby JI, Rudy DC, Hull RA. Pilot trial of bacterial interference for preventing urinary tract infection. Urology 2001;58(3):339-344. (in Engl)
29. Beerepoot MA. Recurrent urinary tract infections. Antibiotic resistance and non-antibiotic prophylaxis [abstract no:SP34-2]. International Journal of Antimicrobial Agents 2013;42(Suppl 2):S38. (in Engl)
30. Reid G, Beuerman D, Heinemann C, Bruce AW. Probiotic lactobacillus dose required to restore and maintain a normal vaginal flora. FEMS Immunology & Medical Microbiology 2001;32(1):37-41. (in Engl)
31. Falagas ME, Betsi GI, Tokas T, Athanasiou S. Probiotics for prevention of recurrent urinary tract infections in women: a review of the evidence from microbiological and clinical studies. Drugs 2006;66(9):1253-61. (in Engl)
32. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck‐Ytter Y, Alonso‐Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6. (in Engl)
33. Haran MJ, Lee BB, King MT, Marial O, Stockler MR. Health status rated with the medical outcomes study 36-item short-form health survey after spinal cord injury. Archives of Physical Medicine & Rehabilitation 2005;86(12):2290-5. (in Engl)
34. Waites KB, Chen Y, DeVivo MJ, Canupp KC, Moser SA. Antimicrobial resistance in gram-negative bacteria isolated from the urinary tract in community-residing persons with spinal cord injury. Archives of Physical Medicine & Rehabilitation 2000;81(6):764-9. (in Engl)
35. Prasad A, Cevallos ME, Riosa S, Darouiche RO, Trautner BW. A bacterial interference strategy for prevention of UTI in persons practicing intermittent catheterization. Spinal Cord 2009;47(7):565-9. (in Engl)
36. Beerepoot MA, Stobberingh EE, Geerlings SE. A study of non‐antibiotic versus antibiotic prophylaxis for recurrent urinary‐tract infections in women (the NAPRUTI study) [Onderzoek naar niet‐antibiotische versus antibiotische profylaxe bij vrouwen met recidiverende urineweginfecties (de NAPRUTI‐studie)]. Nederlands Tijdschrift voor Geneeskunde 2006;150(10):574-5. (in Engl)
37. Haran MJ, King MT, Stockler MR, Marial O, Lee BB. Validity of the SF‐36 Health Survey as an outcome measure for trials in people with spinal injury. www.uts.edu.au/sites/default/files/wp2007_4.pdf (accessed 3 July 2017). (in Engl)
38. Waites KB, Canupp KC, DeVivo MJ. Epidemiology and risk factors for urinary tract infection following spinal cord injury. Archives of Physical Medicine & Rehabilitation 1993;74(7):691-5. (in Engl)
39. Hull R, Rudy D, Donovan W, Svanborg C, Wieser I, Stewart C, et al. Urinary tract infection prophylaxis using Escherichia coli 83972 in spinal cord injured patients. Journal of Urology 2000;163(3):872-7. (in Engl)
40. Thom JD, Wolfe V, Perkash I, Lin VW. Methicillin-resistant staphylococcus aureus in patients with spinal cord injury.Journal of Spinal Cord Medicine 1999;22(2):125-31. (in Engl)
41. Kaynan AM, Perkash I. Neurogenic bladder. In: Frontera WR, Silver JK, Rizzo TD editor(s). Essentials of Physical Medicine and Rehabilitation: Musculoskeletal Disorders, Pain and Rehabilitation. 2nd Edition. Philadelphia: Saunders Elsevier, 2008. (in Engl)
42. Stohrer M, Goepel M, Kondo A, Kramer G, Madersbacher H, Millard R, et al. The standardization of terminology in neurogenic lower urinary tract dysfunction: with suggestions for diagnostic procedures. International Continence Society Standardization Committee. Neurourology & Urodynamics 1999;18(2):139-58. (in Engl)
43. Kilham H, Alexander S, Woods N, Isaacs D. Paediatrics Manual: The Children's Hospital at Westmead Handbook. 2nd Edition. Sydney: McGraw-Hill, 2009. (in Engl)
44. Hawthorn LA, Reid G. Exclusion of uropathogen adhesion to polymer surfaces by Lactobacillus acidophilus. Journal of Biomedical Materials Research 1990;24(1):39-46. (in Engl)
45. Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM, et al. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults.[Erratum appears in Clin Infect Dis. 2005 May 15;40(10):1556]. Clinical Infectious Diseases 2005;40(5):643-54. (in Engl)
46. Kim RC. Spinal cord pathology. In: Lin VW editor(s). Spinal Cord Medicine: Principles and Practice. 2nd Edition. New York: Demos Medical Publishing, 2010:22-34. (in Engl)
47. Laughton J, Devillard E, Heinrichs DE, Reid G, McCormick JK. Inhibition of expression of a staphylococcal superantigen‐like protein by a soluble factor from Lactobacillus reuteri. Microbiology 2006;152(Pt 4):1155-67. (in Engl)
48. Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. (in Engl)
49. Kitagawa T, Kimura T. The influence of complications on rehabilitation of spinal cord injuries: economical minus effects and physical disadvantages caused by urinary tract infection and decubitus ulcer. Journal of Nippon Medical School [Nihon Ika Daigahu Zasshi] 2002;69(3):268-77. (in Engl)
50. Reid G, Bruce AW. Probiotics to prevent urinary tract infections: the rationale and evidence. World Journal of Urology 2006;24(1):28-32. (in Engl)
51. Schwenger EM, Tejani AM, Loewen PS. Probiotics for preventing urinary tract infections in adults and children.Cochrane Database of Systematic Reviews 2015, Issue 12. [DOI: 10.1002/14651858.CD008772.pub2] (in Engl)
52. Schünemann HJ, Oxman AD, Higgins JP, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Stamm WE. Protocol for diagnosis of urinary tract infection: reconsidering the criterion for significant bacteriuria.Urology 1988;32(2 Suppl):6-12. (in Engl)
53. Kariyama Y, R, Kumon H. A pilot study evaluating the safety and effectiveness of Lactobacillus vaginal suppositories in patients with recurrent urinary tract infection. International Journal of Antimicrobial Agents 2006;28 Suppl 1:S30-4. (in Engl)
54. Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] (in Engl)
55. Velraeds MM, Belt-Grittter B, Mei HC, Reid G, Busscher HJ. Interference in initial adhesion of uropathogenic bacteria and yeasts to silicone rubber by a Lactobacillus acidophilus biosurfactant. Journal of Medical Microbiology1998;47(12):1081-5. (in Engl)
56. Fioramonti J, Theodorou V, Bueno L. Probiotics: what are they? What are their effects on gut physiology?. Best Practice & Research Clinical Gastroenterology 2003;17(5):711-24. (in Engl)
57. Schrezenmeir J, Vrese M. Probiotics, prebiotics, and synbiotics approaching a definition. American Journal of Clinical Nutrition 2001;73(2 Suppl):361-4. (in Engl)
58. Girard R, Mazoyer MA, Plauchu MM, Rode G. High prevalence of nosocomial infections in rehabilitation units accounted for by urinary tract infections in patients with spinal cord injury. Journal of Hospital Infection2006;62(4):473-9. (in Engl)
59. Romero-Vivas J, Rubio M, Fernandez C, Picazo JJ. Mortality associated with nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus. Clinical Infectious Diseases 1995;21(6):1417-23. (in Engl)
Review
For citations:
Popov S.V., Huseynov R.G., Sivak K.V., Perepelitsa V.V., Leliavina T.A. PROBIOTICS IN TREATMENT AND PREVENTION OF NEUROGENIC BLADDER INFECTIOUS COMPLICATIONS. Bashkortostan Medical Journal. 2024;19(1):64-70. (In Russ.)
Views:
49
Email this article 
